Wednesday, 22 January 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 22 January 2025
News

Meet the top performers of 2024

Posted 15 January 2025 PM 

An analysis of stock performance over 2024 has identified which Big Pharmas grew the most over 12 months with just over a handful ending the year better than they started and the majority going backwards - but one company was a standout doubling its stock price.

According to the figures, compiled by Swiss-based Senior Market Analyst for KBI Biopharma, Nicolas Schmitz, UCB well and truly out-performed the pack with what was described as "outstanding" sales of its anti-inflammatory drug Bimzelx, which has been PBS listed locally since last July and the company's autoimmune treatment Rystiggo which goes to the PBAC in March. UCB's stock was up 100 per cent for the year.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (5)

Sales & Customer Relations (14)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (2)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.